For investors looking for momentum, First Trust Smallcap Value Alphadex Fund (FYT - Free Report) is probably a suitable pick. The fund just hit a 52-week high and is up 105.4% from its 52-week low price of $18.92/share.
Let’s take a look at the fund and its near-term outlook to gain an insight into where it might be headed:
FYT in Focus
The underlying The NASDAQ AlphaDEX Small Cap Value Index is an enhanced index which employs the AlphaDEX stock selection methodology to select stocks from the NASDAQ US 700 Small Cap Value Index. The fund charges 72 basis points in annual fees.
Why the Move?
Small-caps stocks that are heavily dependent on the domestic economy soared higher on Monday as this beaten-down zone will now be able to take full advantage of the solid economic recovery as vaccine hopes strengthened. Notably, Moderna (MRNA - Free Report) announced on Nov 16 that its experimental vaccine against Covid-19 was 94.5% effective. Last week, Pfizer (PFE - Free Report) and BioNTech (BNTX) also announced that their vaccine candidate was more than 90% effective in avoiding COVID-19. The news explain the latest rally in this small-cap value ETF,
More Gains Ahead?
It seems like the fund will remain strong, with a positive weighted alpha of 17.90, which gives cues of further rally. The current fundamental backdrop looks more promising for the fund.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For investors looking for momentum, First Trust Smallcap Value Alphadex Fund (FYT - Free Report) is probably a suitable pick. The fund just hit a 52-week high and is up 105.4% from its 52-week low price of $18.92/share.
Let’s take a look at the fund and its near-term outlook to gain an insight into where it might be headed:
FYT in Focus
The underlying The NASDAQ AlphaDEX Small Cap Value Index is an enhanced index which employs the AlphaDEX stock selection methodology to select stocks from the NASDAQ US 700 Small Cap Value Index. The fund charges 72 basis points in annual fees.
Why the Move?
Small-caps stocks that are heavily dependent on the domestic economy soared higher on Monday as this beaten-down zone will now be able to take full advantage of the solid economic recovery as vaccine hopes strengthened. Notably, Moderna (MRNA - Free Report) announced on Nov 16 that its experimental vaccine against Covid-19 was 94.5% effective. Last week, Pfizer (PFE - Free Report) and BioNTech (BNTX) also announced that their vaccine candidate was more than 90% effective in avoiding COVID-19. The news explain the latest rally in this small-cap value ETF,
More Gains Ahead?
It seems like the fund will remain strong, with a positive weighted alpha of 17.90, which gives cues of further rally. The current fundamental backdrop looks more promising for the fund.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PFE - FREE
Get the latest research report on MRNA - FREE
Get the latest research report on FYT - FREE